Immunopathological complications of anti-TNF-α biological treatment

Česká verzia

Authors: K. Malíčková
Authors place of work: Klinická imunologie a alergologie – laboratoř, Ústav lékařské biochemie a laboratorní diagnostiky, 1. LF UK a VFN v Praze
Published in the journal: Gastroent Hepatol 2016; 70(1): 45-50
Category: IBD: přehledová práce
doi: https://doi.org/10.14735/amgh2016/csgh.info02

Summary

Biological treatments employing therapeutic monoclonal antibodies against TNF-α are very eff ective and safe, and the side effects of such treatments are usually mild and well-tolerated. However, such treatments are sometimes associated with severe acute and chronic side effects, which have been attributed to secondary immunopathologies induced by TNF-α blockage. Early and delayed hypersensitivity reactions to therapeutic immunoglobulins are most frequent, as well as reactions associated with induced imbalances of the immune system. Cytokine imbalance or antigen cross-reactivity is significantly rarer. This paper reviews the classifi cation and immunopathological complications of anti-TNF-α blockers.

Key words:
infliximab – adalimumab – TNF-α – inflammatory bowel diseases

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
3. 12. 2015

Accepted:
29. 12. 2015

Zdroje

1. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: 2. vydání. Gastroent Hepatol 2012; 66 (1): 12-22.

2. Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003; 17(1): 105-117.

3. Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 2007; 7(7): 1051-1059.

4. Zbořil V. Infliximab v klinické léčebné praxi. Klin Farmakol Farm 2005; 19: 67-71.

5. Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 2008; 40 (Suppl 2): S225-S228. doi: 10.1016/S1590-8658(08)60530-7.

6. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61(8): 912-920.

7. Descotes J. Immunotoxicity of monoclonal antibodies. MAbs 2009; 1(2): 104-111.

8. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108(1): 40-47. doi: 10.1038/ajg.2012.363.

9. Fiorino G, Danese S, Pariente B et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13(1): 15-19. doi: 10.1016/j.autrev.2013.06.005.

10. Visvanathan S, Marini JC, Smolen JS et al. Changes in biomarkers of inflammation and bone turnover and as sociations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 2007; 34(7): 1465-1474.

11. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2(7): 542-553.

12. D’Haens GR, Panaccione R, Higgins PD et al. The London position statement of the World congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106(2): 199-212. doi: 10.1038/ajg.2010.392.

13. Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014; 20(43): 16014-16019. doi: 10.3748/wjg.v20.i43.16014.

14. Stehlík J, Mareš K, Lukáš M et al. Doporučení pro vakcinaci nemocných s Crohnovou chorobou a ulcerózní kolitidou na imunosupresivní a biologické léčbě. Čes a Slov Gastroent a Hepatol 2010; 64(1): 40-48.

15. De Rycke L, Baeten D, Kruithof E et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005, 14(12): 931-937.

16. Atzeni F, Turiel M, Capsoni F et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005; 1051: 559-569.

17. Baert F, De Vos M, Louis E et al. Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg 2007; 70(2): 163-170,

18. Malíčková K, Ďuricová D, Bortlík M et al. Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. Autoimmune Dis 2011; 2011: 945861. doi: 10.4061/2011/945861.

19. Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol 2015; 6:550. doi: 10.3389/fimmu.2015.00550.

20. Katsanos KH, Voulgari PV, Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis 2012; 6(7): 735-742. doi: 10.1016/j.crohns.2012.03.005.

21. Niess JH, Danese S. Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology? Gut 2014; 63(4): 533-535. doi: 10.1136/gutjnl-2013-304683.

22. Til lack C, Ehmann LM, Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63(4): 567-577. doi: 10.1136/gutjnl-2012-302853.

23. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012; 9(9): 496-503. doi: 10.1038/nrgastro.2012.125.

24. Klein G, Klein E. Surveil lance against tumors – is it mainly immunological? Immunol Lett 2005; 100(1): 29-33.

25. Lawrence T. Macrophages and NF-κB in cancer. Curr Top Microbiol Immunol 2011; 349: 171-184. doi: 10.1007/82_2010_100.

26. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999; 117(6): 1433-1437.

27. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-control led trials. Clin Gastroenterol Hepatol 2008; 6(6): 644-653. doi: 10.1016/j.cgh.2008.03.014.

28. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma as sociated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7(8): 874-881. doi: 10.1016/j.cgh.2009.01.004.

29. Deepak P, Sifuentes H, Sherid M et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013; 108(1): 99-105. doi: 10.1038/ajg.2012.334.

30. Beigel F, Steinborn A, Schnitzler F et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014; 23(7): 735-744. doi: 10.1002/pds.3621.

31. Dulai PS, Thompson KD, Blunt HB et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014; 12(9): 1443-1451. doi: 10.1016/j.cgh.2014.01.021.

32. Potter C, Cordell HJ, Barton A et al. As sociation between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010; 69(7): 1315-1320. doi: 10.1136/ard.2009.117309.

33. Tak PP. Role of tumor necrosis factor (TNF) in immune-mediated inflammatory diseases. [online]. Available from: www.medscape.org/viewarticle/545412.